Who is sponsoring NCT00513409?

NCT00513409 is sponsored by GlaxoSmithKline.

What condition does NCT00513409 study?

NCT00513409 studies Infections, Streptococcal.

What drugs are being tested in NCT00513409?

Interventions: Synflorix, Infanrix Hexa, Havrix.

What is the status of NCT00513409?

NCT00513409 is currently COMPLETED.

Last reviewed 2018-12-19 · How we verify

Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule

NCT00513409 PHASE2 COMPLETED Results posted

This is a booster study in 2 groups of healthy children less than 3 years old to measure the reactogenicity, safety and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine, when given as a booster or as a two-dose catch-up vaccination. This protocol posting deals with objectives and outcome measures of the booster phase. The objectives and outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00338351).

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE2
Status	COMPLETED
Enrolment	163
Start date	Wed Aug 22 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Aug 28 2008 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Infections, Streptococcal

Interventions

Synflorix
Infanrix Hexa
Havrix

Countries

Chile